# Nuclide record ken-herrmann (person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/people/ken-herrmann/>
  a schema:Person ;
  nuclide:kind "person" ;
  schema:identifier "ken-herrmann" ;
  schema:name "Ken Herrmann"@en ;
  schema:description "Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes."@en ;
  schema:url <https://nuclide.cc/people/ken-herrmann/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Herrmann%20K%5BAuthor%5D%20theranostics%20PSMA> ;
  nuclide:tag "radioligand", "nuclear-medicine", "germany" ;
  schema:jobTitle "Chair of Nuclear Medicine, University Hospital Essen" ;
  schema:sameAs <https://orcid.org/0000-0002-9662-7259> ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/technologies/fapi-pet/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/>, <https://nuclide.cc/targets/fap/> ;
  nuclide:drugs <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/lutathera/> ;
  nuclide:institutions <https://nuclide.cc/institutions/essen-wtz/>, <https://nuclide.cc/institutions/eanm/> ;
  nuclide:trials <https://nuclide.cc/trials/vision/> ;
  nuclide:keyPapers <https://nuclide.cc/key-papers/paper-vision-nejm-2021/> ;
  schema:affiliation <https://nuclide.cc/institutions/essen-wtz/> .